

Are we throwing good antidepressants out with the swim test water?

Emily R. Trunnell, Ph.D.

Laboratory Investigations Department, People for the Ethical Treatment of Animals, Norfolk, VA, USA

References

1. Adis Insight. Napitane. <https://adisinsight.springer.com/drugs/800005107>. Updated January 24, 2013. Accessed January 18, 2019.
2. Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, Yunis C. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: A randomized trial. *Ann Intern Med*. 2013;159(6):390-400.
3. Bai F, Li X, Clay M, Lindstrom T, Skolnick P. Intra- and interstrain differences in models of "behavioral despair." *Pharmacol Biochem Behav*. 2001;70:187-192.
4. Baldwin D, Hutchison J, Donaldson K, Shaw B, Smithers A. Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. *J Psychopharmacol*. 2008;22(1):55-63.
5. Basso AM, Gallagher KB, Bratcher NA, *et al*. Antidepressant-like effect of D_{2/3} receptor-, but not D₄ receptor-activation in the rat forced swim test. *Neuropsychopharmacol*. 2005;30:1257-1268.
6. Basso AM, Bratcher NA, Gallagher KB, *et al*. Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety. *Eur J Pharmacol*. 2006;540(1-3):115-120.
7. Bautz D. CERC: Encouraging results from proof-of-concept study of CERC-501 in MDD. Yahoo! Finance. <https://finance.yahoo.com/news/cerc-encouraging-results-proof-concept-180000849.html>. Published May 10, 2017. Accessed January 21, 2019.
8. Benvenista MJ, Leander JD. Antidepressant-like effect of LY228729 as measured in the rodent forced swim paradigm. *Eur J Pharmacol*. 1993;239:249-252.
9. Bessalov AY, van Gaalen MM, Sukhotina IA, Wicke K, Mezler M, Schoemaker H, Gross G. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. *Eur J Pharmacol*. 2008;592(1-3):96-102.
10. Beyer CE, Dwyer JM, Piesla MJ, *et al*. Depression-like phenotype following chronic CB1 receptor antagonism. *Neurobiol Dis*. 2010;39:148-155.
11. BlackThorn Therapeutics, Inc. BTRX-246040 administered once daily to patients with major depressive disorder. Identification No. NCT03193398. <https://clinicaltrials.gov/ct2/show/NCT03193398>. Updated September 12, 2018. Accessed January 21, 2019.
12. Bristow LJ, Gulia J, Weed MR, *et al*. Preclinical characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-D-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder. *J Pharmacol Exp Ther*. 2017;363:377-393.
13. Bruns RF, Mitchell SN, Wafford KA, *et al*. Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders. *Neuropharmacology*. 2018;128:351-365.
14. Buckley MJ, Surowy C, Meyer M, Curzon P. Mechanism of action of A-85380 in an animal model of depression. *Prog Neuro-Psychopharmacol Biol Psychiatry*. 2004;28(4):723-730.
15. Buezo, Nuria Diaz, inventor; Eli Lilly and Company, assignee. Kappa selective opioid receptor antagonist. US 7,709,522 B2. May 4, 2010.

16. Cassels A. Whitewashing a black box warning: The Chantix story that didn't get told. <https://www.healthnewsreview.org/2017/01/chantix-black-box-warning/>. Published January 9, 2017. Accessed January 21, 2019.
17. Chappell MD, Li R, Smith SC, *et al.* Discovery of (1S,2R,3S,4S,5R,6R)-2-amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride (LY3020371·HCl): A potent, metabotropic glutamate 2/3 receptor antagonist with antidepressant-like activity. *J Med Chem.* 2016;59:10974-10993.
18. Commons KG, Cholanians AB, Babb JA, Ehlinger DG. The rodent forced swim test measures stress-coping strategy, not depression-like behavior. *ACS Chem Neurosci.* 2017;8:955-960.
19. Dieckmann LHJ, Ramos AC, Silva EA, *et al.* Effects of biperiden on the treatment of cocaine/crack addiction: A randomised, double-blind, placebo-controlled trial. *Eur Neuropsychopharmacol.* 2014;24(8):1196-1202.
20. DrugBank. Moxonidine. <https://www.drugbank.ca/drugs/DB09242>. Updated November 5, 2018. Accessed January 18, 2019.
21. Dressman, Bruce Anthony, inventor; Eli Lilly and Company, assignee. 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as GluR 2/3 antagonists. WO 2012/068041. November 15, 2011.
22. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: A randomized, placebo-controlled clinical trial. *Biol Psychiatry.* 2012;67(5):432-438.
23. Drevets WC, Zarate CA, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: A review. *Biol Psychiatry.* 2013;73(12):1156-1163.
24. Fell MJ, Witkin JM, Falcone JF, *et al.* N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. *J Pharmacol Exp Ther.* 2011;336:165-177.
25. Fritze J. The adrenergic-cholinergic imbalance hypothesis of depression: a review and a perspective. *Rev Neurosci.* 1993;4(1):63-93.
26. Fritze J, Lanczik M, Sofic E, Struck M, Riederer P. Cholinergic neurotransmission seems not to be involved in depression but possibly in personality. *J Psychiatry Neurosci.* 1995;20(1):39-48.
27. Garner JP. The significance of meaning: Why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it? *ILAR J.* 2014;55:438-456.
28. Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. *Biol Psychiatry.* 2011;69(11):1075-1082.
29. Gehlert DR, Rasmussen K, Shaw J, *et al.* Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. *J Pharmacol Exp Ther.* 2009;329:429-438.
30. Geneste H, Bhowmik S, van Gaalen MM, *et al.* Novel, potent, selective and brain penetrant vasopressin 1b receptor antagonists. *Bioorg Med Chem Lett.* 2018;28(19):3260-3264.
31. Giardina WJ, Ebert DM. Positive effects of captopril in the behavioral despair swim test. *Biol Psychiatry.* 1989;25(6):697-702. *J Pharmacol Exp Ther.* 1995;272(3):1160-1169.
32. Gillin JC, Lauriello J, Kelsoe JR, Rapaport M, Golshan S, Kenny WM, Sutton L. No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial. *Psychiatry Res.* 1995;58(2):99-105.
33. Grimwood S, Lu, Y, Schmidt AW, *et al.* Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ -opioid receptors. *J Pharmacol Exp Ther.* 2011;339(2):555-566.

34. Gutman DA, Coyer MJ, Boss-Williams KA, Owens MJ, Nemeroff CB, Weiss JM. Behavioral effects of the CRF1 receptor antagonist R121919 in rats selectively bred for high and low activity in the swim test. *Psychoneuroendocrinol*. 2008;33(8):1093-1101.
35. Hancock AA, Buckner SA, Giardina WJ, *et al*. Preclinical pharmacological actions of (+/-)-(1'R*,3R*)-3-phenyl-1-[1',2',3',4'-tetrahydro-5',6'-methylene-dioxy-1'-naphthalenyl] methyl] pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine. *J Pharmacol Exp Ther*. 1995;272(3):1160-1169.
36. Hasselmann H. Scopolamine and depression: A role for muscarinic antagonism? *CNS Neurol Disord Drug Targets*. 2014;13(4): 673-683.
37. Health Sciences Authority. 11 Oct 2010: Suspension of sales of sibutramine. https://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Safety_Information_and_Product_Recalls/Product_Safety_Alerts/2010/suspension_of_sales.html. Accessed January 18, 2019.
38. Holsboer F, Ising M. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. *Eur J Pharmacol*. 2008;583(2-3):350-357.
39. Kalgutkar AS, Dalvie DK, Aubrecht J, *et al*. Genotoxicity of 2-(3-chlorobenzoyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine_{2c} receptor agonist for the treatment of obesity: Role of metabolic activation. *Drug Metab Dispos*. 2007;35(6):848-858.
40. Keller M, Montgomery S, Ball W, *et al*. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. *Biol Psychiatry*. 2006;59(3):216-223.
41. Lelas S, Li Y, Wallace-Boone TL, *et al*. NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test. *Neuropharmacol*. 2013;73:232-240.
42. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). *Neuropharmacol*. 2001;40:1028-1033.
43. Li X, Witkin JM, Need AB, Skolnick P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. *Cell Mol Neurobiol*. 2003;23(3):419-430.
44. Li X, Need AB, Baez M, Witkin JM. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. *J Pharmacol Exp Ther*. 2006;319:254-259.
45. Li Y, Langdon S, Pieschl R, *et al*. Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats. *Eur J Pharmacol*. 2014;737:47-56.
46. Marion Merrel Limited and Cerebrus Limited. Exhibit 4.4. Lease agreement. <https://www.sec.gov/Archives/edgar/data/851616/000115697303001590/u46725exv4w4.txt>. Dated May 13, 1997. Accessed January 18, 2019.
47. Mental Health Daily. Mirapex (Pramipexole) for depression: An effective antidepressant? <https://mentalhealthdaily.com/2016/02/07/mirapex-pramipexole-for-depression-an-effective-antidepressant/>. Published February 7, 2016. Accessed January 21, 2019.
48. Molendijk ML, de Kloet ER. Immobility in the forced swim test is adaptive and does not reflect depression. *Psychoneuroendocrinol*. 2015;62:389-391.
49. O'Neill, Michael, inventor; Eli Lilly and Company Limited, assignee. Use of moxonidine for the treatment of depression. WO1999020278A1. April 29, 1999.
50. O'Neill MF, Osborne DJ, Woodhouse SM, Conway MW. Selective imidazoline I2 ligands do not show antidepressant-like activity in the forced swim test in mice. *J Psychopharmacol*. 2001;15(1):18-22.
51. Pedrosa, Jose Maria Lopez, inventor; Abbott Laboratories, assignee; Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate. US patent 9,326,956. May 3, 2016.
52. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: An 8-week, open-label study. *J Clin Psychiatry*. 2009;70(7): 1026-1031.

53. Post A, Smart TS, Krikke-Workel J, *et al.* A selective nociception receptor antagonist to treat depression: Evidence from preclinical and clinical studies. *Neuropsychopharmacology*. 2016;41(7):1803-1812.
54. Qato DM, Ozenberger K, Olsson M. Prevalence of prescription medications with depression as potential adverse effect among adults in the United States. *JAMA*. 2018;319(22):2289-2298.
55. Rankovic Z, Hargreaves R, Bingham M. *Drug Discovery for Psychiatric Disorders*. London: Royal Society of Chemistry. 2012.
56. Rollema H, Guanowsky V, Mineur YS, Shrikhande A, Coe JW, Seymour PA, Picciotto MR. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. *Eur J Pharmacol*. 2009;605(1-3):114-116.
57. Rosso M, Muñoz M, Berger M. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. *Sci World J*. 2012;2012:381434.
58. Skolnick, Phil, inventor; Eli Lilly and Company, assignee. Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator. WO 01/89530A1. May 11, 2001.
59. Siuciak JA, Fujiwara RA. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. *Psychopharmacology*. 2004;175:163-169.
60. Siuciak JA, Chapin DS, McCarthy SA, *et al.* CP-809,101, a selective 5-HT_{2C} agonist, shows activity in animal models of antipsychotic activity. *Neuropharmacology*. 2007;52:279-290.
61. Stanford University. Stanford RAD study (research on anxiety and depression). Identification No. NCT02220309. <https://clinicaltrials.gov/ct2/show/NCT02220309>. Updated August 7, 2017. Accessed January 21, 2019.
62. The Taub Group. The safety and efficacy of naltrexone and scopolamine utilized in the treatment of major depression. Identification No. NCT03386448. <https://clinicaltrials.gov/ct2/show/NCT03386448>. Updated April 24, 2018. Accessed January 21, 2019.
63. University of Oxford. Pramipexole and emotional processing (PEP). Identification No. NCT03681509. <https://clinicaltrials.gov/ct2/show/NCT03681509>. Updated September 24, 2018. Accessed January 21, 2019.
64. Valentine RU. Nomifensine (Merital, Alival) controversy. *The SAGE Encyclopedia of Pharmacology and Society*. Ed: Boslaugh SE. 2016.
65. Wallace-Boone TL, Newton AE, Wright RN, Lodge NJ, McElroy JF. Behavioral and pharmacological validation of the gerbil forced-swim test: Effects of neurokinin-1 receptor antagonists. *Neuropsychopharmacology*. 2008;33:1919-1928.
66. Waszkiewicz N, Zalewska-Szajda B, Szajda SD, *et al.* Sibutramine-induced mania as the first manifestation of bipolar disorder. *BMC Psychiatry*. 2012;12:43.
67. Witkin JM, Overshiner C, Li X, *et al.* M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. *J Pharmacol Exp Ther*. 2014;351:448-456.
68. Witkin JM, Rorick-Kehn LM, Benvenga MJ, *et al.* Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. *Pharmacol Res Perspect*. 2016;4(6):e00275.
69. Witkin JM, Shenvi RA, Li X, *et al.* Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies. *Biochem Pharmacol*. 2018;155:61-70.
70. Wohleb ES, Wu M, Gerhard DM, Taylor SR, Picciotto MR, Alreja M, Duman RS. GABA interneurons mediate the rapid anti-depressant-like effects of scopolamine. *J Clin Invest*. 2016;126(7):2482-2494.
71. Yu L, Zhang H, Caldarone BJ, Eaton JB, Lukas RJ, Kozikowski AP. Recent developments in novel antidepressants targeting $\alpha 4\beta 2$ -nicotinic acetylcholine receptors. *J Med Chem*. 2014;57(20):8204-8223.